Literature DB >> 27450106

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.

Silke Gillessen1, Clare Gilson2, Nick James3, Amanda Adler4, Matthew R Sydes2, Noel Clarke5.   

Abstract

Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.
Copyright © 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27450106     DOI： 10.1016/j.eururo.2016.07.015

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  19 in total

1.  Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.

Authors:  Christine G Skibinski; Tara Williamson; Gregory J Riggins
Journal:  J Neurooncol       Date:  2018-11-09       Impact factor: 4.130

Review 2.  Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.

Authors:  Adam B Weiner; Oluwarotimi S Nettey; Alicia K Morgans
Journal:  Curr Treat Options Oncol       Date:  2019-07-09

3.  Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.

Authors:  Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-01-24       Impact factor: 5.554

4.  Metformin promotes proliferation and suppresses apoptosis in Ox-LDL stimulated macrophages by regulating the miR-34a/Bcl2 axis.

Authors:  Liuliu Feng; Tianhua Liu; Yuya Yang; Wenying Xiao; Jun Shi; Xiang Mei; Songmei Tian; Xinbing Liu; Hongman Huang; Yanyan Bai
Journal:  RSC Adv       Date:  2019-05-10       Impact factor: 4.036

Review 5.  The future of clinical trials in urological oncology.

Authors:  Vikram M Narayan; Philipp Dahm
Journal:  Nat Rev Urol       Date:  2019-10-11       Impact factor: 14.432

6.  Cyberknife Radioablation of Prostate Cancer – Preliminary Results for 400 Patients

Authors:  Leszek Miszczyk; Agnieszka Namysł Kaletka; Aleksandra Napieralska; Grzegorz Woźniak; Małgorzata Stąpór Fudzińska; Grzegorz Głowacki; Andrzej Tukiendorf
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01

Review 7.  The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.

Authors:  Boris Y Shorning; Manisha S Dass; Matthew J Smalley; Helen B Pearson
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

8.  Metformin protects against oxidized low density lipoprotein-induced macrophage apoptosis and inhibits lipid uptake.

Authors:  Ning Huangfu; Yong Wang; Jingsong Cheng; Zhenyu Xu; Shenghuang Wang
Journal:  Exp Ther Med       Date:  2018-01-05       Impact factor: 2.447

Review 9.  Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.

Authors:  C Gilson; S Chowdhury; M K B Parmar; M R Sydes
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-10-25       Impact factor: 4.126

10.  Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Authors:  Malcolm D Mason; Noel W Clarke; Nicholas D James; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Gerhardt Attard; William Cross; Rob J Jones; Christopher C Parker; J Martin Russell; George N Thalmann; Francesca Schiavone; Estelle Cassoly; David Matheson; Robin Millman; Cyrill A Rentsch; Jim Barber; Clare Gilson; Azman Ibrahim; John Logue; Anna Lydon; Ashok D Nikapota; Joe M O'Sullivan; Emilio Porfiri; Andrew Protheroe; Narayanan Nair Srihari; David Tsang; John Wagstaff; Jan Wallace; Catherine Walmsley; Mahesh K B Parmar; Matthew R Sydes
Journal:  J Clin Oncol       Date:  2017-03-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.